TuHURA Biosciences, Inc. (HURA) – What Are Investment Firms Saying About This Stock?

Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA) have received a consensus rating of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $9.00.

A number of analysts recently weighed in on the stock. Citizens Jmp reaffirmed a “market outperform” rating and set a $9.00 price target on shares of TuHURA Biosciences in a research report on Tuesday, August 18th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of TuHURA Biosciences in a research note on Tuesday, October 27th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a report on Thursday, October 15th.

Institutional Investors Weigh In On TuHURA Biosciences

Institutional investors have recently made changes to their positions in the company. Two Sigma Securities LLC acquired a new position in TuHURA Biosciences in the second quarter worth $33,000. Merck & Co. Inc. raised its holdings in shares of TuHURA Biosciences by 39.4% during the first quarter. Merck & Co. Inc. now owns 19,445 shares of the company’s stock worth $35,000 after purchasing an additional 5,495 shares during the period. Sanctuary Advisors LLC acquired a new stake in shares of TuHURA Biosciences during the second quarter worth $49,000. Deutsche Bank AG bought a new position in shares of TuHURA Biosciences in the 2nd quarter worth about $52,000. Finally, PFG Investments LLC lifted its position in shares of TuHURA Biosciences by 39.4% in the 1st quarter. PFG Investments LLC now owns 32,630 shares of the company’s stock worth $58,000 after buying an additional 9,219 shares during the last quarter. 0.62% of the stock is currently owned by institutional investors.

TuHURA Biosciences Stock Performance

NASDAQ HURA opened at $1.93 on Friday. TuHURA Biosciences has a fifty-two week low of $0.41 and a fifty-two week high of $3.43. The stock has a market cap of $123.00 million, a price-to-earnings ratio of -3.57 and a beta of -0.21. The business has a fifty day moving average of $2.02 and a 200-day moving average of $1.96. The company has a quick ratio of 0.18, a current ratio of 0.18 and a debt-to-equity ratio of 0.20.

TuHURA Biosciences (NASDAQ:HURA) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. As a group, analysts predict that TuHURA Biosciences will post -0.57 earnings per share for the current fiscal year.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is directed toward treatments intended to address mechanisms that enable tumors to evade the immune system and resist existing cancer therapies.

TuHURA’s lead product candidate, IFx-2, is an investigational cancer immunotherapy designed for intratumoral administration. The program is intended to stimulate a broader anti-tumor immune response and potentially improve the effectiveness of immune checkpoint inhibitors and other established treatments.